LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

Search

Actinium Pharmaceuticals Inc

Uždarymo kaina

1.51 1.34

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.43

Max

1.54

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-9.3M

-16M

Pelnas, tenkantis vienai akcijai

-0.51

Darbuotojai

31

EBITDA

-9.3M

-17M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+302.68% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-01

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

12M

61M

Ankstesnė atidarymo kaina

0.17

Ankstesnė uždarymo kaina

1.51

Actinium Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-16 22:33; UTC

Įsigijimai, susijungimai, perėmimai

KKR to Acquire Australian Power Provider Zenith Energy

2025-06-16 21:55; UTC

Pagrindinės rinkos jėgos

Geospace Technologies Shares Up on Petrobras Pact

2025-06-16 17:04; UTC

Pagrindinės rinkos jėgos

Roku Shares Climb on Advertising Deal with Amazon

2025-06-16 23:51; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-16 23:51; UTC

Rinkos pokalbiai

Nikkei May Trade Range Bound Amid Israel-Iran Conflict -- Market Talk

2025-06-16 23:41; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

2025-06-16 23:10; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

XRG Has 'Viable Path' to Approval of Santos Takeover -- Market Talk

2025-06-16 23:02; UTC

Rinkos pokalbiai

Auckland Airport Unlikely to Hit Target for International Passengers -- Market Talk

2025-06-16 22:32; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Santos Unlikely to Attract Rival Bidder to XRG -- Market Talk

2025-06-16 22:03; UTC

Įsigijimai, susijungimai, perėmimai

KKR & Co. to Buy Zenith Energy From Consortium Including Pacific Equity Partners, OPSEU Pension Trust, Foresight Group >KKR

2025-06-16 22:00; UTC

Įsigijimai, susijungimai, perėmimai

KKR Acquires Leading Australian Independent Power Producer Zenith Energy >KKR

2025-06-16 21:56; UTC

Uždarbis

Lennar Has an Earnings Miss. The Stock Slips. -- Barrons.com

2025-06-16 21:10; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi in Talks to Sign $8 Billion Deal With Gas Producer Aethon -- WSJ

2025-06-16 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-06-16 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-16 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-16 20:49; UTC

Rinkos pokalbiai

Fitch Revises Canadian Provinces Fiscal Outlook to 'Deteriorating' -- Market Talk

2025-06-16 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Update: EchoStar Stock Surges. It's Short Covering and President Trump. -- Barrons.com

2025-06-16 20:13; UTC

Rinkos pokalbiai

Natural Gas Gains on Warmer Outlook -- Market Talk

2025-06-16 19:58; UTC

Įsigijimai, susijungimai, perėmimai

OpenAI and Microsoft Tensions Are Reaching a Boiling Point -- WSJ

2025-06-16 19:13; UTC

Rinkos pokalbiai

Middle-East Conflict May Not Push Up Oil Long Term -- Market Talk

2025-06-16 19:09; UTC

Rinkos pokalbiai

Amazon-Roku Deal Shows Competition for Streaming Ad Space -- Market Talk

2025-06-16 18:43; UTC

Rinkos pokalbiai

May Could Mark Nascent Recovery in Canada Housing Market -- Market Talk

2025-06-16 18:36; UTC

Rinkos pokalbiai

Soybeans May Get Boost from Renewable Fuel Obligations -- Market Talk

2025-06-16 18:29; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-06-16 18:29; UTC

Rinkos pokalbiai

Shopify Appears More Resilient Than Feared -- Market Talk

2025-06-16 18:22; UTC

Rinkos pokalbiai

Citi Forecasts Downturn in Gold Futures -- Market Talk

2025-06-16 16:42; UTC

Rinkos pokalbiai

Homebuyers' Downpayments Are Shrinking For First Time in 2 Years -- Market Talk

2025-06-16 16:37; UTC

Rinkos pokalbiai

Big, Beautiful Bill Might Not Mean Big Growth -- Market Talk

2025-06-16 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Actinium Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

302.68% į viršų

12 mėnesių prognozė

Vidutinis 6 USD  302.68%

Aukščiausias 9 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Actinium Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.